There are different options. It really depends on which one makes the most sense from both a financial regulatory fees perspective and.... There are business cases to be made for both.
The reliance model allows for a licensing in Canada that remains permanent. That product then enters the market and has the potential to stay on the market, as long as the maintenance fees and all the requirements that follow from that, the post-market part of it.... It's probably a more permanent solution for us, in terms of keeping the product here.
In the way that the reliance model is structured as it currently stands right now, and we have the incorporation by reference list, there are still some restrictions and carve-outs. Currently the proposal is that for livestock medications, reliance will apply only to antimicrobial medications—your antibiotics, your antivirals, your antiparasitics, internal antiparasitics—that are licensed in the United States. It will still exclude anything that's licensed in the European Union, the United Kingdom, Australia or New Zealand.